BIA
ITCI

Bell Investment Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bell Investment Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22
Closed -$2.9K – 2001
2025
Q1 		$2.9K Hold
22
– – ﹤0.01% 1159
2024
Q4 		$1.84K Hold
22
– – ﹤0.01% 1367
2024
Q3 		$1.61K Hold
22
– – ﹤0.01% 1437
2024
Q2 		$1.51K Hold
22
– – ﹤0.01% 1469
2024
Q1 		$1.52K Hold
22
– – ﹤0.01% 1459
2023
Q4 		$1.58K Sell
22
-10
-31% -$575 ﹤0.01% 1435
2023
Q3 		$1.67K Sell
32
-15
-32% -$874 ﹤0.01% 1363
2023
Q2 		$2.98K Hold
47
– – ﹤0.01% 1094
2023
Q1 		$2.55K Buy
47
+32
+213% +$1.55K ﹤0.01% 1127
2022
Q4 		$794 Hold
15
– – ﹤0.01% 1647
2022
Q3 		$1K Sell
15
-9
-38% -$470 ﹤0.01% 1650
2022
Q2 		$1K Buy
+24
New +$1.36K ﹤0.01% 1673
2021
Q4 		$1K Hold
15
– – ﹤0.01% 1681
2021
Q3 		$1K Buy
+15
New +$521 ﹤0.01% 1632

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bell Investment Advisors's ITCI Position: Q2 2025 in Review

Bell Investment Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 22 shares — an estimated $2.9K sold.

Bell Investment Advisors first reported a position in ITCI in Q3 2021 and held it in 14 quarters. The position peaked at $2.98K in Q2 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Bell Investment Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Bell Investment Advisors sold 22 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.9K.
  • Bell Investment Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2021 and held it in 14 quarters.
  • Bell Investment Advisors's Intra-Cellular Therapies Inc. position peaked at $2.98K in Q2 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Bell Investment Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.